NEW YORK (360Dx) – Planet Innovation said today that it is collaborating with Preora Healthcare to develop and commercialize a series of cancer screening tests that employ Preora's cytology platform based on partial-wave spectroscopy (PWS) and its sample-preparation technologies.
They expect to first develop a commercial test for first-tier lung cancer screening and later for screening of colorectal cancer, prostate cancer, and other solid-tumor malignancies.
The collaboration between the two companies spans research, design, early-stage manufacturing, and commercial strategy.
Financial and other terms of the collaboration were not disclosed.
Preora's sample-prep technologies and its PWS Nanocytology platform provide levels of sensitivity and specificity that can enable effective screening in primary-care settings, Planet Innovation said. Preora's PWS Nanocytology imaging platform, based on development work at Northwestern University, detects intracellular structural changes of chromatin.
Preora's sample preparation technologies expedite sample triage and improve sample preservation, and that enables precision visualization by PWS Nanocytology Fixed Cell Imaging, Planet Innovation said.
Planet Innovation's Vice President of Venture Business Development Anthony White said in a statement that the firm sees an opportunity for the sample prep technology in underserved segments of the cytology market.